A detailed history of Geode Capital Management, LLC transactions in Ocuphire Pharma, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 265,854 shares of OCUP stock, worth $313,707. This represents 0.0% of its overall portfolio holdings.

Number of Shares
265,854
Previous 234,398 13.42%
Holding current value
$313,707
Previous $471,000 13.8%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.51 - $2.23 $47,498 - $70,146
31,456 Added 13.42%
265,854 $406,000
Q1 2024

May 13, 2024

BUY
$1.89 - $3.27 $28,888 - $49,981
15,285 Added 6.98%
234,398 $471,000
Q3 2023

Nov 13, 2023

BUY
$3.35 - $4.33 $83,964 - $108,527
25,064 Added 12.92%
219,113 $734,000
Q2 2023

Aug 11, 2023

BUY
$3.63 - $6.38 $46,024 - $80,892
12,679 Added 6.99%
194,049 $842,000
Q1 2023

May 15, 2023

BUY
$3.01 - $3.85 $24,992 - $31,966
8,303 Added 4.8%
181,370 $680,000
Q4 2022

Feb 13, 2023

BUY
$2.04 - $3.53 $43,855 - $75,887
21,498 Added 14.18%
173,067 $610,000
Q3 2022

Nov 14, 2022

BUY
$1.82 - $2.79 $7,480 - $11,466
4,110 Added 2.79%
151,569 $304,000
Q2 2022

Aug 12, 2022

BUY
$1.8 - $3.25 $31,563 - $56,988
17,535 Added 13.5%
147,459 $283,000
Q1 2022

May 13, 2022

BUY
$2.75 - $4.39 $106,854 - $170,577
38,856 Added 42.67%
129,924 $420,000
Q4 2021

Feb 11, 2022

BUY
$3.4 - $5.19 $41,293 - $63,032
12,145 Added 15.39%
91,068 $339,000
Q3 2021

Nov 12, 2021

BUY
$3.84 - $5.38 $204,783 - $286,910
53,329 Added 208.37%
78,923 $406,000
Q2 2021

Aug 13, 2021

BUY
$4.24 - $6.57 $60,606 - $93,911
14,294 Added 126.5%
25,594 $135,000
Q1 2021

May 12, 2021

BUY
$5.7 - $13.31 $64,410 - $150,403
11,300 New
11,300 $65,000

Others Institutions Holding OCUP

About Ocuphire Pharma, Inc.


  • Ticker OCUP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,579,800
  • Market Cap $24.3M
  • Description
  • Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical tr...
More about OCUP
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.